CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients.
CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients.
复制标题
DOI：
10.18632/oncotarget.12815
复制
发表时间：
2017-03-21
期刊：
影响因子：
--
通讯作者：
Xu J
中科院分区：
文献类型：
--
作者：
Cao Y;Liu H;Zhang H;Lin C;Li R;Wu S;Li H;He H;Zhang W;Xu J
CXC趋化因子受体1（CXCR1）的异常表达已显示出在多种癌症中促进肿瘤血管生成、侵袭和转移的能力。我们当前研究的目的是发现 CXCR1 在可切除胃癌中的临床预后意义。纳入2007年至2008年在复旦大学附属中山医院接受R0胃切除加标准D2淋巴结清扫术的330例胃癌患者。使用免疫组织化学染色评估 CXCR1 表达。分别考察CXCR1表达与临床病理特征及术后预后的关系。在发现和验证数据集中，CXCR1 高表达表明 TNM II 和 III 患者的总生存期 (OS) 较差。此外，多变量分析确定 CXCR1 表达和 TNM 分期是 OS 的两个独立预后因素。将 CXCR1 表达纳入当前的 TNM 分期系统可以生成一种新型的胃癌临床预测模型，在患者 OS 方面显示出更好的预后准确性。更重要的是，CXCR1 表达较高的 TNM II 患者可从术后基于 5-氟尿嘧啶 (5-FU) 的辅助化疗 (ACT) 中显着受益。 CXCR1在胃癌中被确定为独立的不良预后因素。将CXCR1表达与当前的TNM分期系统相结合可以为胃癌患者带来更好的风险分层和更准确的预后。 CXCR1 的高表达确定了 TNM II 期胃癌患者的亚组，这些患者似乎受益于基于 5-FU 的 ACT。
Abnormal expression of CXC chemokine receptor 1 (CXCR1) has shown the ability to promote tumor angiogensis, invasion and metastasis in several cancers. The purpose of our curret study is to discover the clinical prognostic significance of CXCR1 in resectable gastric cancer. 330 gastric cancer patients who underwent R0 gastrectomy with standard D2 lymphadenectomy at Zhongshan Hospital, Fudan University between 2007 and 2008 were enrolled. CXCR1 expression was evaluated with use of immunohistochemical staining. The relation between CXCR1 expression and clinicopathological features and postoperative prognosis was respectively inspected. In both discovery and validation data sets, CXCR1 high expression indicated poorer overall survival (OS) in TNM II and III patients. Furthermore, multivariate analysis identified CXCR1 expression and TNM stage as two independent prognostic factors for OS. Incorporating CXCR1 expression into current TNM staging system could generate a novel clinical predictive model for gastric cancer, showing better prognostic accuracy with respect to patients’ OS. More importantly, TNM II patients with higher CXCR1 expression were shown to significantly benefit from postoperative 5-fluorouracil (5-FU) based adjuvant chemotherapy (ACT). CXCR1 in gastric cancer was identified as an independent adverse prognostic factor. Combining CXCR1 expression with current TNM staging system could lead to better risk stratification and more accurate prognosis for gastric cancer patients. High expression of CXCR1 identified a subgroup of TNM stage II gastric cancer patients who appeared to benefit from 5-FU based ACT.